Dow Up0.07% Nasdaq Up0.61%

Sarepta Therapeutics, Inc. (SRPT)

16.81 Up 0.29(1.76%) Nov 26, 4:00PM EST
|After Hours : 16.86 Up 0.05 (0.30%) Nov 26, 5:23PM EST
ProfileGet Profile for:
Sarepta Therapeutics, Inc.
215 First Street
Suite 415
Cambridge, MA 02142
United States - Map
Phone: 857-242-3700

Index Membership:N/A
Full Time Employees:146

Business Summary 

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Sarepta Therapeutics, Inc.

Corporate Governance 
Sarepta Therapeutics, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 9. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 3; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Christopher Nishan Garabedian , 47
Chief Exec. Officer, Pres and Director
Mr. Sandesh Mahatme LL.M., 49
Chief Financial Officer, Chief Accounting Officer and Sr. VP
Dr. Jayant Aphale Ph.D., MBA, 54
Sr. VP of Technical Operations
Mr. David Tyronne Howton , 42
Sr. VP, Gen. Counsel and Corp. Sec.
Dr. Edward M. Kaye M.D., Ph.D., 65
Chief Medical Officer and Sr. VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders